Treatment of Type 2 Diabetes: What Have We Learned? AACE Diabetes Algorithm. ADOPT Trial 6/13/2012
|
|
- Lauren Barnett
- 5 years ago
- Views:
Transcription
1 Treatment of Type 2 Diabetes: What Have We Learned? Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering needed, patientspecific concerns, adverse effects, comorbidities, and contraindications Discuss the role of combination therapy and when it should be initiated based on A1C goals Discuss modes of action and clinical potential of recently introduced agents in the management of patients with type 2 diabetes: bromocriptine and colesevelam Explain the implications of recent clinical trials and meta-analyses on clinical practice decisions AACE Diabetes Algorithm Guide to therapy based on A1C level Focus on lifestyle intensification at all levels Initiation as well as maintaining therapy Important tenets: Target A1C is <6.5% Based upon associated lower risk of micro- and macrovascular complications Recommend monitoring A1C quarterly, along with fasting and postprandial blood glucose, with intensification of therapy until goal A1C is achieved Use agents with maximal efficacy associated with lowest risk of hypoglycemia Sulfonylureas are therefore much lower in algorithm Earlier use of incretin mimetics and DPP-4 inhibitors to stimulate insulin secretion without hypoglycemia ADOPT Trial No. at Risk Rosiglitazone Glyburide Kahn et al, N Engl J Med. 2006;355: Kaplan Meier estimates of the cumulative incidence of monotherapy failure at 5 years If patient had a fasting plasma glucose >180 mg/dl, treatment was considered to have failed 4 Additive Effects of Combination Therapy: A1C Changes in Selected Studies of Combination Therapy* A1C % Gly Met Gly Met Met Met Rosi *Not head-to-head trials. /- metformin. Continued monotherapy 10.0 SU 8.7 SU Pio Met Met Exe Exe Combination therapy Met Met Sit Gly = glyburide; Met = metformin; Rosi = rosiglitazone; SU = sulfonylurea; Pio = pioglitazone; Exe = exenatide; = thiazolidinedione; Sit = sitagliptin. DeFronzo R et al. N Engl J Med. 1995;333: ; Fonseca V et al. JAMA. 2000;283: ; Kipnes MS, et al. Am J Med. 2001;111:10-17; DeFronzo RA et al. Diabetes Care. 2005;28: ; Charbonnel B, et al. Diabetes Care. 2004;27: ; Rosenstock J et al. Clin Ther. 2006;28: ; Zinman B et al. Ann Intern Med. 2007;146: Sit Baseline A1C 6.5%-7.5% A1C % Monotherapy MET DPP4 AGI MET or DPP4 Glinide or SU or DPP4 MET 2-3 Mos. Dual Therapy AGI Monotherapy may be effective in this range is cornerstone of rx; first choice for monotherapy if no contraindications Consider DPP-4 if PP and FPG, if PP, if metabolic syndrome or NAFLD, AGI if PP Do not recommend secretagogue (SU or glinide) in this range due to risk of hypoglycemia, short-lived effect If monotherapy is unsuccessful, move on to dual oral rx; often need to augment reduction in PP BG to get to goal in this A1C range still the cornerstone of therapy If metformin is contraindicated, consider as foundation of rx Second component of rx is usually an incretin mimetic, DPP-4 inhibitor,, glinide, or SU, in that order May also consider metformin w/colesevelam or AGI A1C 6.5%-7.5% (cont d) MET Triple Therapy or DPP4 or DPP4 2-3 Mos. SU If dual oral rx is unsuccessful, consider triple therapy Consider 6 main rx options: MET agonist MET agonist glinide MET agonist SU MET DPP-4 MET DPP-4 glinide MET DPP-4 SU When triple oral rx fails to achieve A1C goal, insulin rx is needed Consider addition of basal, premix, prandial or basal-bolus DPP-4 inhibitors (except sitagliptin) and agonists have not been approved for use with insulin Discontinue SU or glinide if prandial insulin is initiated Consider discontinuation of due to fluid retention and weight gain AACE Algorithm for Glycemic Control, Endocr Pract. 2009;15(6):540-59; Sitagliptin Prescribing Information; Merck & Co, Inc,
2 MET Baseline A1C 7.6%-9.0% Presume monotherapy will be inadequate, and A1C % Dual Therapy 2-3 Mos. Triple Therapy MET or DPP4 SU 2-3 Mos. or DPP4 or SU or Glinide or DPP4 recommend going straight to dual oral rx. Recommended options for dual oral rx are: Met agonist Met DPP-4 inhibitor Met Met SU Met Glinide If dual oral rx is unsuccessful, may consider triple therapy Met agonist Met DPP-4 inhibitor Met agonist SU Met DPP-4 inhibitor SU Met SU Again, if triple oral rx fails to achieve A1C goal, insulin therapy is needed Baseline A1C >9.0% If patient is asymptomatic with recent onset of disease and drug naïve, may consider the following dual or triple oral rx regimens: Met agonist Met agonist SU Met DPP-4 inhibitor Met DPP-4 inhibitor SU Met Met SU Met agonist Met DPP-4 inhibitor Symptoms Drug Naive A1C > 9.0% No Symptoms Under Treatment If patient is symptomatic or is already on therapy, insulin should be initiated Once A1C has improved to <7.5%, may consider initiation of dual oral rx with tapering and possible d/c of insulin rx ME T or DPP4 or DPP4 ± SU ± Clinical Considerations Combining therapeutic agents with different modes of action may be advantageous Use insulin sensitizers such as metformin and/or thiazolidinediones as part of the therapeutic regimen in most patients unless contraindicated, or intolerance to these agents has been demonstrated, thiazolidinediones, and incretin mimetics do not cause hypoglycemia However, when used in combination with secretagogues or insulin, these medications may need to be adjusted as blood glucose levels decline Effect of Glucose-lowering Drugs on Patient Weight Therapeutic Options Sulfonylurea 1,2 3,4 Insulin 5,6 7 DPP-4 inhibitor 8 receptor agonist 9 A1C <7.0% Weight Subcutaneous fatpreventable Visceral fat 1. Malone M. Ann Pharmacother. 2005;39: Glipizide [package insert]. New York, NY; Pfizer; Pioglitazone [package insert]. Deerfield, IL: Takeda Pharmaceuticals America; Rosiglitazone [package insert]. Research Triangle Park, NC; GlaxoSmithKline; Nathan DM, et al. Diabetes Care. 2008;31(1): Holman RR. NEJM. 2007;357(17): [package insert]. Princeton NJ; Bristol Meyers Squibb; Sitagliptin [package insert]. Whitehouse Station, NJ; Merck and Co.; Drucker DJ, et al. J Clin Invest. 2007;117(1): hepatic glucose production FPG more than PPG Efficacy A1C 1%-2% Biguanides No weight gain or hypoglycemia GI side effects Lactic acidosis (rare) Renal disease; CHF Combinations available with SU,, repaglinide, and sitagliptin Characteristics of Agonists Efficacy Dosing Side effects Main risk Associated with *Dosing depends on agonist **Liraglutide only Mimic prolonged action of Decrease A1C levels 0.5% 2.0% (Depends on entry of glucose into bloodstream from gut) Once- or twice-daily injection* Nausea, vomiting, weight loss C-cell thyroid tumors**, long-term safety unknown Pancreatitis [package insert]. Princeton NJ; Bristol Myers Squibb; Nathan DM, et al. Diabetes Care. 2008;31: ; Drucker DJ, et al. Lancet. 2006;368: Exenatide [package insert]. San Diego, CA; Amylin Pharmaceuticals;
3 Characteristics of DPP-4 Inhibitors Inhibit enzymatic degradation of and GIP; glucose-dependent Efficacy Decrease A1C levels 0.6% 0.9% Dosing Once daily Side effects Headaches, nasopharyngitis Main risk Viral infection; long-term safety unknown Efficacy Sulfonylureas Glyburide, glipizide, glimepiride insulin secretion FPG PPG Moderate Inexpensive; strong short term efficacy Weight gain, hypoglycemia Avoid in severe hepatic and renal impairment Combinations available with metformin, Rosenstock J, et al. Curr Opin Endocrinol Diabetes Obes. 2007;14: Nathan DM, et al. Diabetes Care. 2008;31: Glyburide [package insert]. New York, NY; Pfizer; Glipizide [package insert]. New York, NY; Pfizer; Glimepiride [package insert]. Scoppito, Italy; Aventis Pharma S.p.A; Thiazolidinediones Pioglitazone, rosiglitazone insulin sensitivity, especially at muscle, lowers both FPG and PPG, but effect may be delayed Efficacy Moderate ( A1C 1.0%-1.5%) No hypoglycemia, no reliance on renal excretion. Fluid retention, edema, heart failure, weight gain, cost, slow onset of action, bone fractures Class III or IV CHF or hepatic impairment w/ ALT >2.5 times upper normal limits Combinations available - and sulfonylurea Synthetic Human Amylin Analog Pramlintide Amylin mimetic: PPG, suppresses glucagon secretion, slows gastric emptying, promotes satiety Efficacy Modest ( A1C 0.5%) No dosage adjustment required in renal impairment Nausea, headaches, anorexia, vomiting, abdominal pain, fatigue, dizziness, coughing, pharyngitis, risk of severe hypoglycemia with insulin Confirmed diagnosis of gastroparesis, hypoglycemia unawareness Rosiglitazone [package insert]. Research Triangle Park, NC; GlaxoSmithKline; Pramlintide [package insert]. San Diego, CA; Amylin Pharmaceuticals, Inc; Efficacy Alpha-Glucosidase Inhibitors Acarbose, miglitol Combinations available: Sulfonylurea Rate of gut polysaccharide breakdown, thereby slowing absorption Modest ( A1C 0.5%-1.0%), PPG lowering Weight-neutral, non-systemic drug, targets post-prandial glucose bloating, flatulence, diarrhea - w/slow titration, frequent dosing, cost Severe renal impairment, Diabetic ketoacidosis, malabsorption, obstruction, inflammatory bowel, or conditions aggravated by gas production. Other Therapies: Likely Effects on Hepatic and Peripheral Insulin Resistance Bromocriptine Acarbose [package insert]. Wayne, NJ; Bayer HealthCare Pharmaceuticals Inc.; Miglitol [package insert]. Wayne, NJ; Bayer HealthCare Pharmaceuticals Inc.;
4 Bromocriptine-QR (quick release) This dopamine receptor agonist is indicated as an adjunct to diet and exercise to improve glycemic control in adults with diabetes BromocriptineEffect on A1C in Combination with Other Oral Hypoglycemic Agents (OHA) Any OHA OHA SulfonylureaOHA GlyburideOHA OHA The specific mechanism by which bromocriptine mesylate improves glycemic control is not known Patients with type 2 diabetes should take bromocriptine mesylate within 2 hours of waking in the morning Bromocriptine An initial daily dose of 0.8 mg should be titrated weekly until a maximum tolerated dose of 1.6 mg to 4.8 mg is achieved Possible decreased risk for CV events with bromocriptine (p<0.0001;bromocriptine n=261; n=151) 2 - (p<0.0001;bromocriptine n=181; n=101) 3 - (p<0.0002;bromocriptine n=121; n=71) 4 - (p<0.0001;bromocriptine n=68; n=36) 5 - (p<0.0026;bromocriptine n=46; n=35) Holt RIG, et al. Diabetes, Obesity and Metabolism. 2010;12: Scranton et al, Diabetologia 2008; 51 (Suppl. 1): S Poster, presented at: EASD Rome, Italy. Cincotta et al, Diabetologia 2008; 51 (Suppl. 1): S22. Poster, presented at: EASD Rome, Italy. Bromocriptine-QR Tolerability Severe adverse events 14% 17% Nausea 7% 22% Orthostatic hypotension 0.8% 2.2% Somnolence 1.3% 4.3% Bromocriptine-QR Psychosis - may exacerbate psychotic disorders or reduce effectiveness of drugs that treat psychosis; not reported with QR formulation to date Cardiovascular Fibrosis Drug interactions (Caution combining) Safety Event rate lower in Bromocriptine-QR than placebo (1.8% vs. 3.2%) in 1-year safety study Associated with ergot-derived dopamine receptor agonists, may be less in bromocriptine-qr Other ergot-related drugs Dopamine receptor agonists or antagonists Strong inhibitors/agonists/substrates of CYP3A4 Fast-Acting Bromocriptine Safety Trial Cumulative Percent Composite CVD Endpoint HR 0.58; 95% CI, RRR=42% Bromocriptine *MI, Stroke, hospitalization unstable angina, hospitalization CHF, or coronary revasc. KM Curve: the separation in favor of Bromocriptine begins 3 months and persists through the end of the study Holt RIG, et al. Diabetes, Obesity and Metabolism. 2010;12: Gaziano M. Diabetes Care, 2010 Jul;33(7): Indicated as an adjunct to diet and exercise as dual or triple therapy to improve glycemic control in adults with type 2 diabetes Not indicated as treatment for type 1 diabetes or DKA of action uncertain : History of bowel obstruction Serum triglycerides >500 mg/dl History of hypertriglyceridemia-induced pancreatitis Effects of on A1C Levels in Add-On Therapy Trials: 0.5% Reductions Mean Change in A1C (%) GLOWS Week * Week 26 Sulfonylurea Week * -0.54* Insulin Week * * P n=>1,000 [Package Insert]. Daiichi Sankyo, Inc., Parsippany, NJ. February Zieve FJ et al. Clin Ther. 2007;29:74. Bays H et al. Presented at: AACE 16th Annual Meeting & Clinical Congress; April Abstract 204. Fonseca VA et al. Presented at: AACE 16th Annual Meeting & Clinical Congress; April Abstract 409. Goldberg RB et al. Presented at: AHA Scientific Sessions; November 2006; Chicago, IL. Poster
5 Dosage and Administration Recommended dosing with meals and a liquid: 625 mg tablets: Take 6 tablets QD OR 3 tablets BID Suspension preparation (powder mixed with water): Take 3.75 g packet QD OR g packet BID As with all LDL-C lowering agents, serum lipid levels should be monitored periodically No special considerations or dosage adjustments with hepatic impairment or renal disease LDL-C=low-density lipoprotein cholesterol in Type 2 Diabetes: Adverse Reactions * Event Description Number of Patients (%) N = 566 N = 562 Constipation 49 (8.7) 11 (2.0) Nasopharyngitis 23 (4.1) 20 (3.6) Dyspepsia 22 (3.9) 8 (1.4) Hypoglycemia 17 (3.0) 13 (2.3) Nausea 17 (3.0) 8 (1.4) Hypertension 16 (2.8) 9 (1.6) *-Controlled Clinical Studies of Add-on Combination Therapy with, Insulin, Sulfonylureas: Adverse Reactions Reported in 2% of Patients and More Commonly than in Patients Given, Regardless of Investigator Assessment of Causality. [Package Insert]. Daiichi Sankyo, Inc., Parsippany, NJ. February [Package Insert]. Daiichi Sankyo, Inc., Parsippany, NJ. February UKPDS: Benefits of Glycemic Control Every 1% decrease in A1C led to significant reductions in diabetes-related complications Effect of Intensive Control of Glucose on Cardiovascular Outcomes and Deaths in Patients with Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials 14% Risk of myocardial infarction 21% Risk of diabetesrelated death 37% Risk of microvascular complications 43% Risk of amputation or PVD Death UKPDS PROactive ADVANCE VADT ACCORD Total N Years Patient- years 46,237 15,059 55,700 10,030 35, ,905 Control 7.9% 7.6% 7.3% 8.4% 7.5% 7.5% Intensive 7.0% 7.0% 6.8% 6.9% 6.4% 6.6% Decrease was statistically significant for all comparisons shown Stratton IM et al. BMJ. 2000;321: Probability of Non-fatal Myocardial Infarction Events with Intensive Glucose-Lowering Versus Standard Treatment Probability of Coronary Heart Disease Eventswith Intensive Glucose-Lowering Versus Standard Treatment Non-fatal myocardial infarction Coronary Heart Disease events 5
6 Probability Strokewith Intensive Glucose-Lowering Versus Standard Treatment Probability of All-cause Mortalitywith Intensive Glucose-Lowering Versus Standard Treatment Stroke All-cause mortality Recent Glycemia Trials The 3 trials: CVD outcomes Action to Control Cardiovascular Risk in Diabetes (ACCORD) Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation (ADVANCE) Veterans Affairs Diabetes Trial (VADT) All conducted in: Older patients ( 60 years) Patients with CVD (1/3 to 1/2 of cohorts) or 1 CVD risk factors ACCORD ADVANCE VADT Intensive Standard Intensive Standard Intensive Standard Baseline 8.1% 8.1% 7.5% 7.5% 9.4% 9.4% Final 6.4% 7.5% 6.4% 7.0% 6.9% 8.4% CVD/year 2.1% 2.3% 2.0% 2.1% 3.8% 4.9% Ray et al. Lancet. 2009;373: The Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008; 358: Abraira, C, et al. J Diab Comp, 2003; Patel, A. et al. N Engl J Med, 2008;358: The 3 Trials: Severe Hypoglycemia ACCORD ADVANCE VADT Intensive Standard Intensive Standard Intensive Standard (% / year) 3.1% 1.1% 0.7% 0.4% 12.0% 4.0% Meta-Analysis: Cardiovascular Risk With Sulfonylurea Plus Results With Combination Therapy Increased composite cardiovascular risk end point (RR 1.43; 95% CI, ) All-cause mortality alone not significant Cardiovascular disease mortality alone not significant Bruno (1999) Olsson (2000) Relative Risk (95% CI) 1.04 ( ) 1.86 ( ) 0.96 ( ) 1.38 ( ) Evans (2006) (B) Evans (2006) (C) Overall 2.24 ( ) 1.86 ( ) 1.52 ( ) 1.43 ( ) Composite end point: cardiovascular hospitalization or mortality Relative risk: combination therapy vs. diet, metformin alone, or sulfonylurea alone RR = relative risk The Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008; 358: Abraira, C, et al. J Diab Comp, 2003; Patel, A. et al. N Engl J Med, 2008;358: Rao AD, et al. Diabetes Care. 2008;31:
7 Higher Mortality Is Associated With Greater Exposure to Sulfonylurea There was a greater risk of death associated with higher daily doses and better adherence for patients who used glyburide (HR = 1.3; 95% CI, ), but not metformin (HR = 0.8; 95% CI, ) Monotherapy group Glyburide (n= 4138) (n = 1537) Daily Dose Deaths/1000 person-years Lower (higher) 53.4 (70.2) 41.5 (37.6) Hazard ratio Unadjusted Adjusted for age, sex, chronic disease score (CDS), and nitrate use Adjusted for age, sex, CDS, nitrate use, physician visits, and hospital admissions Monotherapy group Glyburide (n = 4138) (n = 1537) A retrospective, inception cohort study conducted in 5795 new users of oral glucose-lowering medications - Insulin or combination therapy were excluded - Mean age: 66.3 years Adherence Deaths/1000 person-years Poor (good) 49.0 (75.8) 37.7 (41.3) Hazard ratio Mean follow-up: 4.6 years - Main outcomes: all-cause mortality, death from acute ischemic event Implications for Clinical Care The lack of significant reductions in CVD events should not lead clinicians to abandon the general target A1C of <7.0% or 6.5% There is still a proven reduction in microvascular complications! Need comprehensive care for diabetes involving lipids, BP, and glycemic control Simpson SH, et al. CMAJ. 2006;174: Skyler JS, et al. J Am Coll Cardiol 2009;53: Glucose and Cardiovascular (CV) Risk If other CV risk factor control is good, there is no additional CV benefit of lowering A1C from 8.4% to 6.9% in older people with advanced DM (VADT) If other CV risk factor control is good, there may be CV harm in lowering A1C from 7.5% to 6.4% in older people with advanced DM (ACCORD), perhaps due to hypoglycemia (VADT) PROactive Study >5,000 patients in 19 European countries involving over 320 investigators Investigated effect of insulin resistance on CV morbidity and mortality in T2DM Investigated pioglitazone ability to prevent progression of macrovascular disease The Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med. 2008; 358: Patel, A. et al. N Engl J Med, 2008;358: PROspective Actos Clinical Trial In macrovascular Events (PROactive) results. Accessed February Primary & Secondary Endpoints PROactive Study Primary endpoints: Time to first occurrence of any of the following events from time of randomization: All-cause mortality Stroke Leg revascularization Non-fatal MI (including silent) Major leg amputation (above the ankle) Acute coronary syndrome Cardiac intervention Secondary endpoints: Time to first occurence of any of the of the following events from randomization: Non-fatal MI Stroke All-cause mortality PROactive Study Secondary endpoints: No Significant Effect of Pioglitazone on Primary Composite CV Kaplan-Meier Event Rate Time to ACS PIO (35/1230) (54/1215) HR 95% CI P value placebo ,.035 PIO vs 0.97 Endpoints Kaplan-Meier Event Rate Time to Fatal/Nonfatal MI (excluding silent MI) PIO vs placebo PIO (65/1230) (88/1215) HR 95% CI P value , N at (139) N at (139) Risk: Risk: l l l l l l l l l l l l l l l l Time From Randomization (mo) Time From Randomization (mo) ACS=acute coronary syndromes PROactive results Web site. Available at The official PROspective Actos Clinical Trial In macrovascular Events results.com (PROactive) results website. Available at Accessed January 12, /html/analysis.htm. October 10, PROspective Actos Clinical Trial In macrovascular Events (PROactive) results. Accessed February Dormandy JA, et al. Lancet. 2005;366:
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationUpdate on Oral Agents for T2DM and Obesity
Update on Oral Agents for T2DM and Obesity This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved,
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationUpdate on Oral Agents for T2DM and Obesity
AACE 2016 To AACE Update on Oral Agents for T2DM and Obesity This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationAACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM. Sherwin D Souza, MD, FACE
AACE/ACE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM Sherwin D Soza, MD, FACE Prediabetes Treatment Algorithm T2DM = type 2 diabetes mellits BP = blood pressre CVD = cardiovasclar disease
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More information5/18/2011. Diabetes: Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Diabetes: 2011 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Pre Test Questions 1. There is evidence that lowering A1c reduces the risk of both micro- and macrovascular disease. A. True
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact DIABETES
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationThiazolidinedione Step Therapy Program
Thiazolidinedione Step Therapy Program Policy Number: 5.01.580 Last Review: 7/2018 Origination: 07/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationCURRENT STATEGIES IN DIABETES MELLITUS DIABETES. Recommendations for Adults CURRENT STRATEGIES IN DIABETES MELLITUS. Diabetes Mellitus: U.S.
CURRENT STATEGIES IN DIABETES MELLITUS Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Diabetes Mellitus: U.S. Impact ~1 Million Type 1 DIABETES 16.7 Million IFG (8.3%) 12.3
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationOld oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
More informationMetformin. Sulfonylurea. Thiazolidinedione. Insulin
동아의대내분비내과박미경 Metformin Sulfonylurea Thiazolidinedione Insulin 요약 markers of inflammation (hs-crp, TNF-a) markers of impaired endothelial function (VFW, scams, tpa, PAI-1) LDL-C, fasting and postprandial
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationCONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE. AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY. sul Paziente ad alto rischio CV*
CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY sul Paziente ad alto rischio CV* Does reducing hyperglycemia protect against cardiovascular risk?
More informationDiabetes Mellitus: Overview and Guidelines
Diabetes Mellitus: Overview and Guidelines Rezvan Salehidoost, M.D., Endocrinologist Abidi Diabetes Master Class IMPORTANCE? Why is it interesting to do research in diabetes J. Olefsky, JAMA 2001:285:628-632
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Noninsulin Treatment of Diabetes: What the PCP Needs to Know
Non Insulin Treatment of Type 2 Diabetes: What the PCP Needs to Know Martin J. Abrahamson, MD Senior Vice President for Medical Affairs Joslin Diabetes Center Associate Professor of Medicine Harvard Medical
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2011 BMI
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationCurrent evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
More informationComparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes
Draft Comparative Effectiveness Review Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department
More informationRebecca Newberry APRN MS CDE
Current Diabetes Medications Nursing Implications and Applications Rebecca Newberry APRN MS CDE Methodist Center for Diabetes and Nutritional Health Disclosures Objectives Speakers Bureaus/Consulting Board
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationIt is estimated that approximately 20.8 million Americans
FORMULARY MANAGEMENT Managed Care Perspective on Three New Agents for Type 2 Diabetes Shawna VanDeKoppel, PharmD; Hae Mi Choe, PharmD, CDE; and Burgunda V. Sweet, PharmD, FASHP ABSTRACT BACKGROUND: Despite
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More information효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 ( ) 가천의대길병원내분비대사내과
효과적인경구혈당강하제의조합은? 대한당뇨병학회제 17 차연수강좌 (2011.10.30.) 가천의대길병원내분비대사내과 박이병 내용 배경 경구혈당강하제의병합이왜필요한가? (WHY?) 경구혈당강하제의병합은언제시작하나? (WHEN?) 경구혈당강하제의병합은어떻게하는것이좋은가?(HOW) 맺음말 배경 : drugs for treating diabetes In 1995 :
More informationFixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University
Fixed dose combination for Trusted Diabetes Control By Lobna Farag Eltooy Head of Internal Medicine Department 1 Assiut University 3/18/2018 3/18/2018 3/18/2018 Diabetes Complications with Increasing HbA1c
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationEvidence-Based Glucose Management in Type 2 Diabetes
Evidence-Based Glucose Management in Type 2 Diabetes James R. Gavin III, MD, PhD CEO and Chief Medical Officer Healing Our Village, Inc. Clinical Professor of Medicine Emory University School of Medicine
More informationAACE/ACE Consensus Statement
AACE/ACE Consensus Statement Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic
More information9/12/2014. Main Pathophysiological Defect in T1DM. Main Pathophysiological Defects in T2DM. Personalizing Diabetes Care: The Alphabet Soup of Options
9/12/2014 Baptist Health South Florida 13th Annual Primary Focus Symposium June 28, 2014 Silvio Inzucchi MD Section of Endocrinology Yale University School of Medicine Half-Century of HTN & T2DM Medications
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More information